Frederic Triebel, MD, PhD (Prima Biomed) shared pre-clinical data for IMP321, which is a LAG-3Ig fusion protein that binds to major histocompatibility complex (MHC) class II molecules on the surface of APC and triggers activation of APC and CD8+ T cells known to mediate tumor recognition and killing. Here, CD8A is linked to neoplasm.